Iron / TIBC / Saturation: Drugs That Distort This Test

What Iron, TIBC, and Transferrin Saturation Actually Measure

The iron/TIBC/TSAT panel gives three distinct but interdependent data points. Serum iron measures the amount of iron bound to transferrin in circulation. TIBC reflects the total capacity of transferrin to carry iron. Transferrin saturation divides serum iron by TIBC and multiplies by 100, expressing the percentage of transferrin binding sites currently occupied by iron.

Serum Iron

Serum iron alone is a noisy signal. It fluctuates by as much as 30% across the day, peaks in the morning, and drops sharply after a large iron-rich meal or a supplement dose taken the prior evening. A single low serum iron is therefore never sufficient to diagnose deficiency [1].

Total Iron-Binding Capacity

TIBC is an indirect measure of transferrin concentration. When the body is iron-depleted, the liver upregulates transferrin synthesis and TIBC rises. When iron is overloaded, TIBC falls as transferrin is fully saturated and production is suppressed. Inflammation independently suppresses transferrin synthesis, which means a low TIBC in a hospitalized patient does not reliably point to overload [2].

Transferrin Saturation

TSAT is the most diagnostically stable of the three values because it normalizes iron against binding capacity. The WHO defines iron-deficiency erythropoiesis as TSAT <16% [3]. The American Association for Clinical Endocrinology (AACE) and the 2022 KDIGO guidelines for chronic kidney disease anemia both recommend TSAT as the primary screening metric alongside ferritin when evaluating functional iron deficiency [4].

Normal Ranges and How to Read Them

Reference intervals differ slightly by laboratory method and analyzer, but the widely cited adult ranges are:

| Marker | Reference interval | Units | |---|---|---| | Serum iron | 60 to 170 | mcg/dL | | TIBC | 240 to 450 | mcg/dL | | Transferrin saturation | 20 to 50 | % |

A TSAT below 20% with a TIBC above 380 mcg/dL and a low ferritin (<30 ng/mL) strongly suggests true iron deficiency. A TSAT above 45% with a ferritin above 200 ng/mL in a non-acutely ill patient triggers evaluation for HFE-related hemochromatosis [5].

Pediatric and Pregnancy Differences

Pregnant women normally carry a lower TIBC floor around 300 mcg/dL in the first trimester, which expands to 400 to 500 mcg/dL by the third trimester as transferrin production rises to meet fetal demand [6]. Children younger than 5 have proportionally lower serum iron values (roughly 50 to 120 mcg/dL) and slightly higher TIBC. Applying adult cutoffs to a third-trimester patient or a toddler will over-diagnose deficiency or miss it entirely, depending on which direction you err.

Diurnal Variation and Fasting Requirements

Morning fasting is required for a valid serum iron draw. One crossover study in 24 healthy adults found that a 100 mg oral iron dose taken the evening before raised next-morning serum iron by a mean of 40 mcg/dL above baseline [1]. The clinical instruction: draw the panel fasting before 10 a.m. And hold all oral iron supplements for at least 24 hours.

Drugs That Falsely Raise Serum Iron or TSAT

Several drug classes increase measured serum iron or TSAT without reflecting true body iron status.

Oral and Intravenous Iron Supplements

This is the most common source of interference. Oral ferrous sulfate, ferrous gluconate, and ferrous bisglycinate all transiently raise serum iron by 30 to 100 mcg/dL within 2 to 4 hours of ingestion and can remain elevated for 12 to 24 hours. Intravenous iron (ferric carboxymaltose, iron sucrose, low-molecular-weight iron dextran) produces a sharp spike in serum iron lasting 24 to 48 hours; the FDA labeling for ferric carboxymaltose (Injectafer) explicitly states that serum iron and TSAT should not be measured within 24 hours of an IV iron infusion [7]. Ferritin may remain elevated for weeks after IV iron, a separate distortion.

Chloramphenicol

Chloramphenicol blocks mitochondrial protein synthesis in red cell precursors, impairing iron utilization for hemoglobin synthesis. Unused iron accumulates in serum. Published case series document serum iron values exceeding 250 mcg/dL in patients receiving therapeutic chloramphenicol courses of 10 to 14 days [8]. This is a false elevation: body iron stores are not elevated, and the picture resembles sideroblastic anemia on bone marrow biopsy.

Oral Contraceptives and Estrogen Therapy

Exogenous estrogens upregulate hepatic transferrin synthesis. A meta-analysis of 14 studies (combined N = 3,812 women) found that combined oral contraceptives raised serum TIBC by a mean of 38 mcg/dL and raised serum iron by a mean of 11 mcg/dL compared with non-users [9]. TSAT therefore rises modestly, not because the patient has more iron but because both numerator and denominator shift. Clinicians interpreting iron panels in women on estrogen-containing contraceptives or menopausal hormone therapy should note this effect; a TSAT of 28% in an OCP user might correspond to only 22% in the same patient off the pill.

Testosterone Therapy

Exogenous testosterone raises hemoglobin and stimulates erythropoiesis, increasing iron utilization. However, high-dose testosterone also suppresses hepcidin via erythropoietic signaling, which allows more iron absorption and can raise TSAT. A 2020 prospective cohort study (N = 188 transgender men initiating gender-affirming testosterone) found TSAT increased by a mean of 6 percentage points over 12 months of therapy [10]. In men receiving supraphysiologic testosterone doses for muscle-building, TSAT values above 50% are not uncommon.

Methotrexate and Folate Antagonists

Methotrexate impairs DNA synthesis in erythroid progenitors, reducing red cell production and therefore iron utilization. Serum iron may drift upward by 15 to 25 mcg/dL during chronic low-dose methotrexate therapy (7.5 to 25 mg/week) used for rheumatoid arthritis or psoriasis [2]. The elevation is typically mild, but it can push a borderline TSAT above the 45% threshold and prompt unwarranted hemochromatosis workup.

Drugs That Falsely Lower Serum Iron or TSAT

A separate list of agents suppresses measured iron or expands the apparent binding capacity, mimicking deficiency.

Deferoxamine and Oral Iron Chelators

Deferoxamine (Desferal), deferasirox (Exjade), and deferiprone (Ferriprox) are prescribed to treat iron overload in transfusion-dependent thalassemia and sickle cell disease. They bind serum iron directly, lowering measurable serum iron to near-undetectable levels within hours of infusion. A serum iron drawn while a patient is on active deferoxamine infusion will read falsely low, sometimes <10 mcg/dL, even when iron stores remain elevated [11]. Ferritin is the correct monitoring marker during chelation therapy, not serum iron or TIBC.

Adrenocorticotropic Hormone (ACTH) and Glucocorticoids

Corticosteroids suppress transferrin synthesis and increase iron storage in the reticuloendothelial system. Patients on prednisone 20 mg/day or higher for more than two weeks may show serum iron values 20 to 35 mcg/dL below their pre-treatment baseline [2]. This can falsely suggest the development of iron deficiency in a patient whose actual iron stores are unchanged. Checking ferritin in parallel usually clarifies the picture.

Metformin

This is less widely recognized. Metformin at doses of 1,500 to 2,000 mg/day reduces intestinal iron absorption by an uncertain mechanism, possibly involving effects on DMT-1 (divalent metal transporter-1) expression. A 2019 cross-sectional analysis of NHANES data (N = 2,104 adults with type 2 diabetes) found metformin users had a mean serum iron 8 mcg/dL lower and a mean TIBC 14 mcg/dL higher than matched non-users, yielding a mean TSAT 3 percentage points lower [12]. The absolute difference is small, but in patients near the diagnostic threshold for deficiency, it matters.

Erythropoiesis-Stimulating Agents (ESAs)

Erythropoietin alfa (Epogen), darbepoetin alfa (Aranesp), and other ESAs rapidly accelerate red cell production, consuming iron faster than it can be mobilized from stores. This produces a functional iron deficiency pattern: serum iron falls, TIBC may rise slightly, and TSAT drops below 20%, even when ferritin remains above 100 ng/mL. The KDIGO 2022 guidelines for CKD anemia specify that ESA therapy should not be initiated or escalated when TSAT is <20%, precisely because ESAs create a demand-driven iron depletion that a low TSAT already signals [4].

Aspirin and NSAIDs (Chronic Use)

Chronic aspirin or NSAID use causes subclinical GI blood loss in a meaningful proportion of users. This is not a direct assay interference but a pharmacologically induced true iron loss. A 52-week double-blind trial found that daily aspirin 325 mg caused fecal blood loss averaging 2 to 5 mL/day in 30% of participants, enough to create a negative iron balance of roughly 1 to 2 mg/day and progressively lower serum iron and TSAT over months [13]. Ordering the panel without documenting NSAID use obscures the mechanism of any detected deficiency.

Pre-Analytical Factors Beyond Drugs

Drug effects do not exist in isolation. Several non-pharmacologic factors distort the same markers and must be considered together when reviewing a panel that seems inconsistent with the clinical picture.

Acute-Phase Reaction

Ferritin is a positive acute-phase reactant. Serum iron is a negative one. Any infection, surgery, or inflammatory flare within the prior 72 hours will raise ferritin and lower serum iron independently of true iron status. In a patient with active COVID-19, rheumatoid flare, or post-operative day 1, the iron/TIBC/TSAT panel is essentially uninterpretable without a concurrent C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR) to contextualize it [2].

Hemolysis in the Sample Tube

Red blood cells contain roughly 1,000 times the iron concentration of plasma. Even mild in-vitro hemolysis from a difficult draw or delayed processing can raise serum iron by 20 to 50 mcg/dL. Laboratories flag hemolyzed samples, but mildly hemolyzed samples may pass quality control and still distort results. Requesting a redraw on a new sample is the correct response to an unexpectedly high serum iron without other clinical correlates.

Specimen Timing and Collection Container

EDTA tubes chelate calcium and some divalent metals. Serum (red-top or gold-top SST) is the required collection container for iron studies. Drawing into the wrong tube can reduce measured serum iron by up to 15%. Order "serum iron" and verify with the processing laboratory that a serum tube was used.

A Practical Decision Framework for Clinicians

Reading the iron/TIBC/TSAT panel in isolation produces errors. The following four-step sequence minimizes distortion-driven misdiagnosis.

Step 1. Document all interfering exposures before ordering. Ask specifically about: iron supplements (including multivitamins with iron), oral contraceptives or hormone therapy, metformin dose, corticosteroid use, recent ESA infusion, and IV iron in the prior 48 hours.

Step 2. Time the draw correctly. Fasting, morning draw. Hold oral iron for a minimum of 24 hours. Hold IV iron for at least 48 hours. If the patient cannot hold ESAs, interpret TSAT with the functional deficiency threshold of 20%, not the standard 16%.

Step 3. Pair TSAT with ferritin and a CRP. A low TSAT with a ferritin above 100 ng/mL and an elevated CRP points to anemia of inflammation, not true deficiency. A low TSAT with ferritin below 30 ng/mL and a normal CRP is true iron deficiency until proven otherwise [5].

Step 4. Confirm ambiguous results before treating. If a patient on combined oral contraceptives shows TSAT of 48%, order an HFE gene mutation panel before diagnosing hemochromatosis. If TSAT is 14% in a patient on 2,000 mg/day metformin with a borderline-normal ferritin of 35 ng/mL, a therapeutic trial of iron is diagnostically reasonable, with repeat labs at 8 weeks.

Iron Deficiency vs. Overload: What the Full Pattern Looks Like

Understanding the directional shifts expected in each condition makes drug-induced distortions easier to spot.

Iron Deficiency Pattern

Classic iron deficiency shows low serum iron (below 60 mcg/dL), high TIBC (above 400 mcg/dL), and a TSAT below 16%. Ferritin falls below 30 ng/mL in absolute deficiency, though the WHO sets the population-level repletion threshold at 70 ng/mL for children and pregnant women [3]. A drug that suppresses serum iron and raises TIBC (such as metformin or a glucocorticoid) mimics this pattern exactly.

Iron Overload Pattern

Hereditary hemochromatosis (HFE C282Y homozygosity) presents with high serum iron, low TIBC, and TSAT above 45 to 50%, often accompanied by ferritin above 300 ng/mL in men or above 200 ng/mL in women. An oral contraceptive that raises both serum iron and TIBC may raise TSAT just above 45% in a woman with borderline iron stores, spurring a hemochromatosis workup that would have been negative on a drug-free baseline.

Functional Iron Deficiency

Functional deficiency occurs when iron is present in stores but cannot be mobilized fast enough for erythropoiesis. It is the dominant pattern in CKD patients on ESAs and in patients with chronic inflammation. TSAT falls below 20%, serum iron is low, TIBC may be normal or low (because inflammation suppresses transferrin), and ferritin is normal or elevated. No drug removes iron from the body in this scenario; the deficiency is in delivery speed, not total supply [4].

How Hormonal Therapies Specifically Affect the Panel

Given HealthRX's clinical focus on hormone therapy, GLP-1 agents, and peptides, a brief summary of the most relevant hormonal interferences is warranted.

Estradiol and Progestins

As noted above, estrogen-containing therapies raise TIBC and serum iron modestly. Transdermal estradiol produces a smaller hepatic first-pass effect than oral estradiol, and the effect on TIBC is correspondingly smaller, roughly 15 to 20 mcg/dL versus 30 to 40 mcg/dL with oral dosing [9]. Clinicians monitoring iron status in menopausal patients on oral estradiol should be aware that a TSAT of 40 to 45% may represent a drug effect rather than early overload.

Testosterone (TRT)

Testosterone therapy raises hematocrit via erythropoietic stimulation and hepcidin suppression. Hepcidin, the master iron regulator produced by the liver, is downregulated by erythropoietic drive, allowing more duodenal iron absorption. In men on TRT with a rising hematocrit (above 52%), a concurrent TSAT above 50% is a signal to check ferritin and consider dose reduction or therapeutic phlebotomy per Endocrine Society 2018 TRT guidelines [14]. Rechecking TSAT 4 to 6 weeks after a dose reduction, before attributing the elevation to a primary iron disorder, is the correct sequence.

GLP-1 Receptor Agonists

Semaglutide, liraglutide, and tirzepatide reduce food intake substantially. A secondary effect of reduced dietary intake is reduced iron consumption. In STEP-1 (N = 1,961), semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo (P<0.001) [15]. Patients losing 15% or more of body weight over 12 to 18 months may reduce total dietary iron intake enough to gradually lower TSAT by 3 to 5 percentage points. This is not a direct assay interference, but it is a clinically relevant pharmacological effect on iron balance that should prompt a baseline iron panel before initiating GLP-1 therapy and a repeat panel at 6 to 12 months in patients with rapid weight loss.